Observations placeholder
Aricept
Identifier
015647
Type of Spiritual Experience
Background
A description of the experience
Donepezil, marketed under the trade name Aricept by its developer Eisai and partner Pfizer, and now sold as a generic by multiple suppliers, is a centrally acting reversible acetylcholinesterase inhibitor. Its main therapeutic use is in the palliative treatment of Alzheimer's disease. Common side effects include gastrointestinal upset. It has an oral bioavailability of 100% and easily crosses the blood–brain barrier. Because it has a biological half-life of about 70 hours, it can be taken once a day.
An acetylcholinesterase inhibitor (often abbreviated AChEI) or anti-cholinesterase is a chemical that inhibits the acetylcholinesterase enzyme from breaking down acetylcholine, thereby increasing both the level and duration of action of the neurotransmitter acetylcholine.
On Mar, 1, 2015: 14,911 people reported to have side effects when taking Aricept. Among them, 410 people (2.75%) have Hallucination.
Time on Aricept when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 28.81% | 27.12% | 13.56% | 18.64% | 6.78% | 3.39% | 1.69% |
Gender of people who have Hallucination when taking Aricept :
| Female | Male | |
| Hallucination | 58.41% | 41.59% |
Age of people who have Hallucination when taking Aricept :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Hallucination | 0.00% | 0.26% | 0.00% | 0.00% | 0.00% | 1.32% | 5.29% | 93.12% |
Severity of Hallucination when taking Aricept :
| least | moderate | severe | most severe | |
| Hallucination | 14.29% | 42.86% | 42.86% | 0.00% |
How people recovered from Hallucination :
| while on the drug | after off the drug | not yet | |
| Hallucination | 0.00% | 0.00% | 100.00% |
On Dec, 28, 2016 17,869 people reported to have side effects when taking Aricept.
Among them, 549 people (3.07%) have Death